Acquisition of Atrin Pharmaceuticals (Tables)

12 Months Ended

Dec. 31, 2023

Acquisition of Atrin Pharmaceuticals

Schedule of net assets acquired based on the estimated fair values

Acquired IPR&D	$	76,020,184
Cash and cash equivalents		2,489,745
Prepaid expenses and other assets		34,579
Accounts payable and accrued liabilities		(2,336,462)
Total Acquisition Value	$	76,208,046